Rose McNulty

New Jersey

Associate Editorial Director at MJH Life Sciences

Managing Editor at American Journal of Managed Care

✏️Muscle & Fitness, M&F Hers, Men's Fitness Instagram: @rose_mcnulty

Articles

Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

1 week ago | ajmc.com | Rose McNulty

Shorter venetoclax duration did not significantly impact overall survival (OS) in a real-world cohort of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) treated at a community hospital.1 The findings, presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, suggest that shorter-duration venetoclax could be as effective as longer-duration venetoclax.
Democrats Introduce Bill to Create Public Medicare “Part E”

1 week ago | ajmc.com | Rose McNulty

Representatives Jimmy Gomez (D, California) and Don Beyer (D, Virginia) on Monday introduced the Choose Medicare Act, which would establish a Medicare “Part E” allowing employers and the public to opt into Medicare.1 Senators Jeff Merkley (D, Oregon) and Chris Murphy (D, Connecticut) introduced companion legislation in the Senate.
Hospital Management Involvement Impacts Health-Related Social Needs Program Adoption

1 week ago | ajmc.com | Rose McNulty

When multiple levels of management were involved in health equity goals, acute-care hospitals were more likely to adopt initiatives focusing on health-related social needs (HRSNs), a study published in JAMA Network Open found.1The findings suggest that engaged hospital leadership can help drive change and promote health equity through programs related to HRSNs such as health behaviors, transportation, food insecurity, interpersonal violence, or employment.
RGX-202 Gene Therapy Improves DMD Trajectory, Biomarkers

2 weeks ago | ajmc.com | Rose McNulty

RGX-202, an investigational gene therapy for Duchenne muscular dystrophy (DMD), showed consistent evidence of efficacy based on functional and biomarker data in an interim analysis of the phase 1/2 AFFINITY DUCHENNE trial (NCT05693142), according to a press release from developer REGENXBIO.1Interim results among the first 5 participants in the dose level 2 (2x1014 GC/kg) cohort demonstrated consistent benefits at 9 and 12 months with RGX-202 vs natural history controls.
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

2 weeks ago | ajmc.com | Rose McNulty

A new tablet formulation of zanubrutinib (Brukinsa; BeOne) has been approved by the FDA for all 5 indications, making zanubrutinib the overall market share leader for Bruton tyrosine kinase (BTK) inhibitors, according to a press release from BeOne Medicines.1 Zanubrutinib, a second-generation BTK inhibitor, is approved for the treatment of mantle cell lymphoma, Waldenström’s macroglobulinemia, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, marginal zone lymphoma, and...
Structured Exercise Program Improves Outcomes, Quality of Life in Colon Cancer

3 weeks ago | ajmc.com | Rose McNulty

Patients with stage III or high-risk stage II colon cancer who participated in a 3-year structured exercise program beginning after adjuvant chemotherapy showed improved disease-free survival (DFS), overall survival (OS), and patient-reported physical function compared with patients who received health education materials and standard surveillance, according to research presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and published in the New England Journal...
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial

3 weeks ago | ajmc.com | Rose McNulty

First-line zanubrutinib (Brukinsa; BeiGene) monotherapy demonstrated durable clinical benefits and manageable safety in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with deletion of the 17p chromosome—del(17p)—in a 5-year follow-up analysis of the SEQUOIA trial (NCT03336333).1 The findings were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

3 weeks ago | ajmc.com | Rose McNulty

First-line luspatercept may offer significant advantages over erythropoiesis-stimulating agents (ESAs) for anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), according to a real-world study presented at the 2025 American Society of Clinical Oncology annual meeting.1The study, which evaluated interim data from an ongoing retrospective review of medical records, supports earlier clinical trial findings of luspatercept’s efficacy.
CDC: Measles Vaccine Strongly Recommended for All International Travelers

3 weeks ago | patientcareonline.com | Rose McNulty

The CDC has updated its guidance on measles vaccination for international travelers, recommending that all travelers be fully vaccinated against measles regardless of their international destinations.1While the CDC recommends all US residents receive 2 doses of a measles-containing vaccine to protect against the highly contagious virus,2 the agency previously also stressed the vaccination’s importance for those traveling to countries with outbreaks.
FDA Launches Agency-Wide AI Tool to Aid in Scientific Review

3 weeks ago | ajmc.com | Rose McNulty

The FDA launched a generative artificial intelligence (AI) tool, dubbed Elsa, designed to help employees such as scientific reviewers and investigators work more efficiently, the agency announced in a press release on Monday. The tool, which was built within a high-security GovCloud environment, “modernizes agency functions and leverages AI capabilities to better serve the American people,” the release explained.